Angela J. Yoon was named director of the MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource, effective Dec. 1; she will oversee a growing collection of cancer-associated biospecimens that allow researchers to translate Biological discoveries into prevention, diagnosis and treatment of cancer.
The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.
